

# Recommendations and Standardization of Biomarker Quantification Using NMR-Based Metabolomics with Particular Focus on Urinary Analysis

Abdul-Hamid Emwas,<sup>\*,†</sup> Raja Roy,<sup>‡</sup> Ryan T. McKay,<sup>§</sup> Danielle Ryan,<sup>||</sup> Lorraine Brennan,<sup>⊥</sup> Leonardo Tenori,<sup>#</sup> Claudio Luchinat,<sup>▽</sup> Xin Gao,<sup>○</sup> Ana Carolina Zeri,<sup>◆</sup> G. A. Nagana Gowda,<sup>¶</sup> Daniel Raftery,<sup>+</sup> Christoph Steinbeck,<sup>■</sup> Reza M. Salek,<sup>■</sup> and David S. Wishart<sup>□</sup>

<sup>†</sup>Imaging and Characterization Core Lab, KAUST, Thuwal 23955-6900, Kingdom of Saudi Arabia

<sup>‡</sup>Centre of Biomedical Research, formerly, Centre of Biomedical Magnetic Resonance, Sanjay Gandhi Post-Graduate Institute of Medical Sciences Campus, Lucknow, Uttar Pradesh, India

<sup>§</sup>Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada

<sup>||</sup>School of Agricultural and Wine Sciences, Charles Sturt University, Bathurst, New South Wales, Australia

<sup>⊥</sup>UCD Institute of Food and Health, UCD, Belfield, Dublin, Ireland

<sup>#</sup>FiorGen Foundation, 50019 Sesto Fiorentino, Florence, Italy

<sup>▽</sup>Centro Risonanze Magnetiche – CERM, University of Florence, Florence, Italy

<sup>○</sup>Computational Bioscience Research Center, Computer, Electrical and Mathematical Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of Saudi Arabia

<sup>◆</sup>Brazilian Biosciences National Laboratory, LNBio, Campinas, São Paulo, Brazil

<sup>¶</sup>Northwest Metabolomics Research Center, Department of Anesthesiology and Pain Medicine, University of Washington, 850 Republican Street, Seattle, Washington 98109, United States

<sup>+</sup>Northwest Metabolomics Research Center, Department of Anesthesiology and Pain Medicine, University of Washington, 850 Republican Street, Seattle, Washington 98109, United States


<sup>▽</sup>Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, Seattle, Washington 98109, United States

<sup>■</sup>European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom

<sup>□</sup>Department of Biological Sciences, University of Alberta, Edmonton, Alberta, Canada

**ABSTRACT:** NMR-based metabolomics has shown considerable promise in disease diagnosis and biomarker discovery because it allows one to nondestructively identify and quantify large numbers of novel metabolite biomarkers in both biofluids and tissues. Precise metabolite quantification is a prerequisite to move any chemical biomarker or biomarker panel from the lab to the clinic. Among the biofluids commonly used for disease diagnosis and prognosis, urine has several advantages. It is abundant, sterile, and easily obtained, needs little sample preparation, and does not require invasive medical procedures for collection. Furthermore, urine captures and concentrates many “unwanted” or “undesirable” compounds throughout the body, providing a rich source of potentially useful disease biomarkers; however, incredible variation in urine chemical concentrations makes analysis of urine and identification of useful urinary biomarkers by NMR challenging. We discuss a number of the most significant issues regarding NMR-based urinary metabolomics with specific emphasis on metabolite quantification for disease biomarker applications and propose data collection and instrumental recommendations regarding NMR pulse sequences, acceptable acquisition parameter ranges, relaxation effects on quantitation, proper handling of instrumental differences, sample preparation, and biomarker assessment.

**KEYWORDS:** NMR, urine, disease, metabolites, quantitative analysis, recommendations, standardization, quantification



Received: September 19, 2015

Published: January 8, 2016

## 1. INTRODUCTION

Metabolomics (also known as metabonomics) is the study of global metabolite profiles in biological samples such as biofluids, cell extracts, and tissues. Metabolomics can be integrated with other omics sciences such as genomics, transcriptomics, and proteomics to facilitate a more complete understanding of global biological systems. Metabolite concentrations and perturbations represent a snapshot of the metabolic dynamic that reflect the response of living systems to environmental factors, pathophysiological stimuli, or genetic modification. To characterize the vast array of metabolites found in any given biosample, metabolomics researchers must utilize a wide range analytical platforms including high-performance liquid chromatography (HPLC),<sup>1</sup> liquid chromatography with mass spectrometry (LC-MS),<sup>2</sup> gas chromatography with mass spectrometry (GC-MS),<sup>2a,b,3</sup> tandem mass spectrometry,<sup>4</sup> and NMR spectroscopy.<sup>5</sup> Each technique has its own advantages and disadvantages, and the choice of a given analytical platform often depends on the focus of the study and the samples.<sup>6</sup>

The use of NMR in metabolomics is particularly appealing to many researchers because of its nondestructive, quantitative nature and its ability to identify novel compounds via their unique spectral patterns.<sup>7</sup> In NMR-based metabolomics, biological fluids such as serum, plasma, urine, saliva,<sup>8</sup> cerebrospinal fluid,<sup>9</sup> amniotic fluid,<sup>10</sup> synovial fluid,<sup>11</sup> exhaled breath condensate,<sup>12</sup> cell extracts,<sup>13</sup> and tissue extracts<sup>7g,14</sup> have all proven to be particularly amenable to NMR analysis. Urine, in particular, is a very appealing biofluid for analysis because it is abundant, can be collected noninvasively, and is particularly rich in terms of its chemical diversity. Consequently, urine offers significant opportunities for data mining, data modeling, and biomarker discovery, particularly with respect to human health and disease.<sup>15</sup> Furthermore, urine exhibits a strong phenotypic or metabotypic stability,<sup>16</sup> which strengthens its potential for biomedical research and clinical utility.

Urine is composed primarily of small hydrophilic molecules such as sugars, organic acids, amino acids, soluble lipids, organic amines, and so on, along with inorganic salts that are small enough to have successfully passed through the body's reticuloendothelial filtration system. While the noninvasive collection of urine is advantageous for many metabolomics applications, the major spectroscopic challenge associated with analyzing urine by NMR is the tremendous variation in its chemical concentrations. There are a number of factors, including sample collection and processing, as well as data acquisition and processing parameters, that need to be considered to enable accurate and precise quantitation of urinary metabolites by NMR-based metabolomics. Metabolic profiling of urine gives a time-averaged representation of an individual's recent (typically within 24 h) homeostatic condition. Some metabolites may associate with individual's physiological or pathological state, whereas others may associate with an individual's genotype, environmental exposures, dietary habits, or drug intake<sup>17</sup> as well as the time (season, hour of the day) of collection. Indeed, one of the most significant unresolved issues in urinary metabolomics lies in the remarkable variance in urinary excretion volumes and subsequent variations in metabolite concentrations.<sup>18</sup> As such, it is critical that in quantitative metabolomics the inter- and intraindividual metabolite variance within the normal/control group be properly identified, defined,<sup>18</sup> and as much as possible minimized. This may be facilitated by requiring a 12 h fast prior to urine collection or restricting the consumption of

supplemental protein performance enhancing food, such as protein shakes, prior to any sample collection.<sup>19</sup> Even with these controls in place, the variance in urine metabolite concentrations is still quite significant.

In light of these challenges, a coherent standard protocol is particularly important for the analysis of urinary biomarkers. To ensure robust and accurate quantification of potential urinary biomarkers by NMR, each step of the analytical protocol must be carefully performed and evaluated. This includes appropriate consideration for the context of the chosen application. For example, in nutritional intervention studies, it is important that a standardized diet is introduced to participants prior to the intervention and subsequent sample collection to minimize dietary effects confounding the results. Specifically, sample collection, preservation, preparation as well as instrumental optimization, NMR pulse sequence selection, and choice of acquisition parameters, data-processing parameters, peak/metabolite identification confidence, and final reporting results must be undertaken with a high level of consistency and an appropriate degree of scientific rigor to ensure the validity of the results. This process is not entirely straightforward, and much research has been devoted to refining, testing, and optimizing each step of the NMR analytical and data processing protocols.<sup>7d,20</sup> Indeed, more than 70 papers have been published on the subject since 1990, with one of the most widely cited of these being the publication by Beckonert et al.<sup>20b</sup> While advocating the need for standardized protocols in metabolomic applications (i.e., the Metabolomics Standards Initiative),<sup>21</sup> these authors also noted that it may be "detrimental to the exploratory nature of the subject to allow only "validated" or "approved" procedures to be used in experimental metabolism studies." This acknowledges the importance of further research and improved methodologies for sample handling, data acquisition, and data analysis.

In a previous Review<sup>22</sup> we proposed several recommendations regarding the standardization of the experimental conditions for using urine in NMR-based metabolomic studies. We highlighted the effects of diet, sample collection time (of day), age, gender, gut microflora, individual metabolotypes, physical activity, subject selection, sample storage, salt, and pH effects as well as acquisition temperature with regard to urine metabolite composition and concentrations. We also provided recommendations regarding ethical guidelines for sample acquisition, the establishment of written SOPs, the selection of containers/consumables, patient/sample selection protocols, sample collection handling methods (centrifugation, additives, storage protocols), sample transfer methods, sample pH, chemical shift referencing, minimum sample numbers, sample randomization, magnetic field strength, optimal NMR pulse sequences, acquisition temperature, and results or reporting standards.

In this Review, we will discuss the pertinent issues regarding NMR-based urinary metabolomics with a specific emphasis on quantification for disease biomarker applications. We first review and discuss some of the key issues relating to (1) biomarker assessment, (2) urinary biomarkers and the need for metabolite quantification, (3) metabolite quantification methods for NMR, (4) examples of NMR-derived biomarkers, and (5) concentration normalization methods. Consensus recommendations will then be made regarding: concentration normalization, suitable NMR pulse sequences, acceptable parameter ranges, the effects of relaxation on quantitation, and the utility of data acquired on different instruments

## 2. BIOMARKERS AND BIOMARKER ASSESSMENT

A biomarker is a measurable substance in a biofluid or biological tissue that can be used as an indicator of some biological perturbation caused by a disease, a change in biological state, or an environmental exposure. Biomarkers may be used for disease diagnosis, prognosis, prediction, or monitoring as well as for measuring biological responses from various drug, toxin, or environmental exposures. Biomarkers have a wide range and may include chemicals, metabolites, genes/mutations, RNA transcripts, proteins, cell counts or cell types, karyotypes, or just about any other detectable substance or measurable biological feature. As a general rule, a single biomarker often corresponds to a single medical test, with a threshold value (concentration or number) being used to distinguish between healthy and diseased states.

### 2.1. Biomarker Sensitivity and Specificity


The performance of a biomarker is typically evaluated by its sensitivity and specificity. Sensitivity relates to the biomarker's ability to identify positive results and specificity relates to the biomarker's ability to identify negative results. More specifically, sensitivity can be defined as "the proportion of patients who are known to have the disease who test positive for it", while specificity can be defined as "the proportion of patients that are known not to have the disease who will test negative." The mathematical definition of sensitivity and specificity is given here

$$\begin{aligned} \text{sensitivity} &= \frac{\text{number of true positives}}{\text{number of true positives} + \text{number of false negatives}} \\ &= \frac{\text{number of true positives}}{\text{number of positives}} \end{aligned} \quad (1)$$

$$\begin{aligned} \text{specificity} &= \frac{\text{number of true negatives}}{\text{number of true negatives} + \text{number of false positives}} \\ &= \frac{\text{number of true negatives}}{\text{number of negatives}} \end{aligned} \quad (2)$$

In common medical practice, sensitivity is generally not sufficient to assess the diagnostic performance of a test where the test has no negative predictions (from a theoretical point of view, 100% sensitivity). Therefore, both sensitivity and specificity should be examined together and reported in disease diagnostic studies. Figure 1 demonstrates the assessment of biomarker performance, in the context of a biomarker's ability to differentiate between diseased and healthy subjects.<sup>23</sup> Table 1 summarizes the relationship between positive and negative test outcomes and of true/false positives and negatives.

Simultaneous measurement of both sensitivity and specificity with respect to different separation threshold values is often best illustrated using a receiver operating characteristic (ROC) curve. An ROC curve shows how the sensitivity and specificity change as the classification decision boundary is varied across the range of available biomarker scores. An ROC curve is not dependent on the prevalence of a given outcome, and because it shows the performance of a biomarker test over the complete range of possible decision boundaries, it allows the optimal specificity or sensitivity to be determined posthoc. ROC curves are often summarized into a single metric known as the "area under the curve" (AUC). For a perfect biomarker test, the AUC is 1.0. An AUC of 0.5 is equivalent to randomly classifying subjects (i.e., the



**Figure 1.** Demonstration of the biomarker prediction test with two Gaussian curves indicating the distributions of measured values, with positive cases on the right side and negative cases on the left. The dashed lines indicate the cutoff threshold of hypothetical biomarker concentration that can be used to separate positive from negative tests. The overlap between the biomarker concentrations of the two populations represents the misclassification ratio between the left-hand side of the positive cases and the right-hand side of the negative cases. TP, the number of true positives; TN, the number of true negatives; FP, the number of false positives; FN, the number of false negatives, respectively.<sup>23</sup>

**Table 1. Relationship between Terms of Positive and Negative Test Outcomes**

	condition positive	condition negative
positive test outcome	true positive	false positive
negative test outcome	false negative	true negative

classifier is of no practical utility). A rough guide for assessing the utility of a biomarker based on its AUC is as follows: 0.9 to 1.0 = excellent; 0.8 to 0.9 = good to very good; 0.7 to 0.8 = fair; 0.6 to 0.7 = poor; 0.5 to 0.6 = fail. ROC curve analysis and using ROC-AUC is widely considered to be the most objective and statistically valid method for biomarker performance evaluation. A much more detailed review of ROC analysis along with general recommendations for biomarker quantification and statistical strategies for multibiomarker models is provided elsewhere.<sup>23</sup>

## 3. BIOMARKERS AND METABOLITE QUANTIFICATION

Metabolites and metabolite concentrations can be particularly sensitive to modest physiological or subtle genetic perturbations. Observed changes to urine have historically been accredited to attempts to diagnose ailments as far back as the ancient Greek physician Hippocrates (400 BC) and the Arabian/Persian alchemist Avicenna (11th century). Indeed, as Sir Archibald Garrod (the founder of modern clinical chemistry) noted in 1908, changes in metabolite concentrations often start before the onset of clinical symptoms.<sup>24</sup> This simple fact has served as the basis to the development of more than 180 different chemical or metabolite biomarker tests that are commonly used today (<https://labtestsonline.org>). Indeed, there are more approved metabolite- or chemical-based clinical tests than approved genetic, protein, or karyotype tests (<https://labtestsonline.org>). While most clinical tests are blood-based, an increasing number of clinical assays that use urine currently exist. The very first clinical assay (and the first genetic disease test) was designed for detecting homogentisic acid among individuals with a rare inborn error of metabolism called alkaptonuria.<sup>24</sup> Among the most commonly used metabolite tests today are urinary glucose tests for monitoring diabetes,<sup>25</sup> 24 h urinary creatinine tests to measure kidney function,<sup>26</sup> urinary cortisol tests to diagnose Cushing's or Addison's disease, urinary nitrite tests to detect

**Table 2. Examples of Urinary Biomarkers of Disease Discovered Using NMR-Based Metabolomics in Human Studies**

condition	comparison	biomarkers	reference
pancreatitis	pancreatitis patients vs controls	citrate adenosine	61
bladder cancer	bladder cancer patients vs controls	hippurate citrate taurine	62
hepatocellular carcinoma	hepatocellular carcinoma v cirrhosis vs noncirrhotic liver disease patients vs controls	inosine indole-3-acetate galactose NAA	63
pancreatic ductal adenocarcinoma	pancreatic ductal adenocarcinoma vs controls	acetone hypoxanthine o-acetylcarnitine dimethylamine	76
esophageal cancer	esophageal patients vs controls	urea acetate pantothenate 3-hydroxyisovalerate acetone formate	77
gestational diabetes (GDM)	GDM patients vs controls	3-hydroxyisovalerate 2-hydroxyisobutyrate	78
neonatal health	small vs appropriate for gestational age	glycine threonine	65
neonatal health	intrauterine growth retardation vs controls	myo-inositol sarcosine creatine creatinine	64

bacterial infections, and urinary bilirubin tests to assess liver function (Table 2).

Almost all approved clinical chemistry tests, whether they measure chemical or protein biomarkers, are required to be quantitative or at least semiquantitative (via some ratio measurement). This requirement has allowed universal reference values for different ages and genders to be developed and applied for routine medical diagnoses. In many cases physicians and clinical chemists are required to know or memorize threshold values for a large number of medically important metabolites and proteins. Absolute quantification not only gives physicians useful reference or decision-making thresholds but also ensures consistency and reproducibility from instrument to instrument, lab to lab, city to city, and country to country. As previously stated, the issue of quantification has turned out to be an Achilles heel for many biomarker tests developed using “omics” platforms.<sup>15b,27</sup> This is because proteomic, transcriptomic, and even most metabolomic assays were not originally designed with comparative quantitation in mind, nor were they designed to be compared accurately and precisely between different instrumental platforms.

However, there is now a growing shift in the “omics” community toward developing quantitative proteomic and quantitative metabolomic assays<sup>5g,23,28</sup> with a long-term goal of using these quantitative assays for biomarker discovery, development, and clinical translation.<sup>23</sup> The need for quantification, either relative or absolute, is particularly acute for metabolite-based urine analysis where individual metabolite concentration values can vary by a factor of 10 or more due to dilution, gender, diet, or diurnal effects.<sup>29</sup> As a result there have been a number of papers, NMR-specific software tools (Chenomx, AMIX,

Batman,<sup>30</sup> Bayesil,<sup>31</sup> etc.), as well as a number of commercial kits that have been developed (such as the BioCrates kit for mass spectrometers) to perform absolute metabolite quantification. Methods to facilitate urinary metabolite quantification, with a specific focus on NMR, are briefly reviewed in the next section.

#### 4. QUANTITATION OF METABOLITES BY NMR

NMR spectroscopy is a powerful analytical approach for both identification and quantification of analytes with superior advantages, such as being nondestructive, highly reproducible, and, most importantly, requiring minimal sample preparation.<sup>32</sup> Indeed, NMR is inherently a quantitative technique as the intensity of an NMR signal is proportional to the concentration of detectable (usually <sup>1</sup>H) nuclei in the receiver coil.<sup>33</sup> The 1D <sup>1</sup>H NMR spectra of urine samples are highly complex, with thousands of distinct signals visible in a single spectrum. Consequently, signal overlap and signal distortions from nearby (strong) peaks are often evident even in 1D <sup>1</sup>H NMR spectra collected at 800 MHz and above. Over the past two decades, several methods had been proposed or developed to address these issues. In particular, an exhaustive technical review on this subject has recently been published by P. Giraudeau.<sup>34</sup> This paper nicely summarizes the strengths and weaknesses of various 2D NMR methods, for example, 2D J-resolved, COSY, TOCSY, 2D INEPT, HSQC, HMBC, and so on, with regard to resolution in the second dimension and with respect to compound identification and quantification in complex mixtures. Common shortcomings identified for all (conventional) 2D NMR methods were the lack of sensitivity, the lack of speed, and the difficulties in reproducible quantitation compared to 1D NMR; however, this paper also highlighted several novel 2D NMR methods or data-processing techniques that appear to solve or at least address some of these issues. For instance, 2D <sup>1</sup>H INAD-EQUATE with sparse sampling/nonlinear sampling (NLS) as proposed by Hyberts et al.<sup>35</sup> seems to be very promising for characterizing and quantifying low abundance metabolites. More recently, another approach has been proposed,<sup>36</sup> wherein three different collection and processing techniques were combined, including J-compensated 2D HSQC, NLS, and forward entropy (FM) reconstruction. This combination resulted in a 22-fold reduction in NMR recording time (relative to a conventional HSQC spectrum) while at the same time yielding precise metabolite quantitation in both native and lyophilized urine samples. The authors report a lower limit of detection of “tens of micromolar”; however, these types of experiments are not straightforward, and significant prior knowledge about the sample and expected spectral windows is needed to properly implement the method. Furthermore, while these approaches are promising, they have yet to be implemented in a real, nontargeted metabolomic study nor have they been comprehensively evaluated and validated. Ultrafast 2D NMR spectroscopy<sup>37</sup> is yet another promising method; however, this approach requires sophistication in pulse field gradient performance and specific processing software, presently not available on most commercially available NMR spectrometers. Nevertheless, given its speed, resolution, and sensitivity advantages over fast heteronuclear NMR and even 1D homonuclear NMR methods, this approach may soon become the method of choice for identifying and quantifying low abundance metabolites in urine samples.

Unlike MS-based quantitative methods, which usually require expensive isotopically labeled standards and time-consuming

Table 3. Experimental Conditions for Precise Quantitation of Urine Samples Using NMR Spectroscopy

sample preparation	parameters and recommended values	comments
sampling	overnight fasting urine collection	ensures more stable homeostatic concentrations of metabolites
	mid stream urine collection	avoids unwanted contamination from urinary tract
sample processing	collecting urine sample in labeled tube containing sodium azide (NaN <sub>3</sub> )	to stop bacterial growth in samples; final concentration of 0.05% wt/vol
	store immediately in to -40 to -80 °C until NMR experiments are performed	helps arrest metabolic activities and sample degradation
	centrifugation/filtration	centrifuge at 1000 rpm to remove the turbidity from unwanted particulates, or filter using 0.22 μ filter to remove any macromolecular content in the sample
	phosphate buffer	phosphate buffer helps in avoid chemical shift drift that occurs due to pH variations
	internal reference standard; e.g., TSP or DSS	in protein/lipid free urine sample, TSP and DSS are a good choices as internal standards for quantification and normalization
	use of deuterated EDTA	only recommended when variation of ionic concentration urine is very large and drift in the chemical shifts is causing quantitative errors.
acquisition parameters	one-dimensional gradient NOESY with water presaturation experiment.	
	time domain points (TD): 64K	Increased resolution
	line broadening (lb): 0.1–0.5 Hz	
	relaxation delay >5.0 s	relaxation delay depends on longitudinal relaxation time ( $T_1$ ) of metabolite resonances; it should be five times $T_1$ for absolute quantitation or matched to the $T_1$ of the reference spectra used for deconvolution.
	acquisition time: 2.5 s	increased resolution
	spectral width (sw): 12 ppm	
	number of scan (ns): 64	for desired S/N, more are required for diluted samples
	dummy scan (ds): 8	to achieve steady state prior to acquisition
	excitation pulse: 90 deg	shorter pulse widths can be used for single pulse NMR analysis
	receiver gain (rg): optimal	either a constant RG for all or auto optimized for every sample
processing parameters	mixing time ( $t_m$ ):	pulse sequence requirements for NOESY; minor loss in signal intensity due to transverse relaxation
	100 ms for standard experiment	
	10 ms for gradient experiment	
	sample temperature: 300 K	kept constant throughout the study
	shimming, tune, and match: for every sample	increased accuracy, precision, and reproducibility
	windowing: exponential window function with line broadening of 0.3–1.0 Hz	
	zero filling: a factor of 2 of TD	increased resolution
	phase correction: manual phasing is preferred	optimal for accurate integration of peaks area
	baseline correction: automatic/manual	increased accuracy of peak integration
	chemical shift referencing	both TSP and DSS can be used for chemical shift referencing ( $\delta$ 0.0), although DSS is the IUPAC standard

chromatographic separations, NMR spectroscopy offers the possibility of quantifying many metabolites simultaneously without the need for any prior chromatographic separation; however, accurately and reproducibly quantifying NMR signals from different instruments at different field strengths and using different pulse sequences or pulse widths and delay times is often challenging. Indeed, despite a steady increase in the number of publications arising from NMR-based metabolomics focused on diagnostic biomarkers, only a few of these report quantified metabolite levels.<sup>23,29a,38</sup> This paucity of quantitative data could be due to the fact that metabolite quantification is both instrumentally challenging and manually intensive work.

In terms of instrumental issues, the greatest challenge in NMR-based quantification lies in consistency and reproducibility. To obtain consistent and reliable results, identical NMR tubes must be used as well as identical instrument parameters including temperature, chemical shift referencing, tuning, shimming, magnetic field drift compensation/lock, pulse sequences, water suppression methods, acquisition times, and data-processing parameters (Table 3). These conditions must be strictly adhered to from sample to sample. This not only allows for rigorous quality assurance but also allows robust intralaboratory and

interlaboratory comparison. Variations in the ionic strength of different samples can have dramatic effects on the ability to tune and match the spectrometer (assuming the probe range is sufficient), leading to profoundly different pulse widths or spectrometer responses. Specifically, what are assumed to be infinitely short “on-resonance” pulses become ineffective (much less than 90°) and contain larger and larger off-resonance pulse effects (evolution). This can have dramatic consequences regarding relaxation of the NMR signal in-between data acquisitions. In addition, some instrumental effects (e.g., field instability, temperature variations, incorrect referencing) can cause chemical shift changes. Recently, Sokolenko et al. evaluated the sources of quantification variability in NMR and determined that such seemingly mundane issues as sample insertion methods or shimming protocols as well as the choice of NMR pulse sequence could lead to significant differences in the resulting metabolite identification and quantification.<sup>39</sup> It has also been shown that the data acquisition parameters, spectral processing parameters, and the choice of water suppression method can also substantially affect metabolite quantification results.<sup>40</sup>

As a general rule, a single excitation pulse sequence with a relatively low-power water presaturation is the default method

for performing quantitative metabolite analysis of biofluids and biological extracts. Historically, quantitation in NMR required the use of long pulse delays to allow signals to fully recover, but more recently the use of a low flip angle (i.e.,  $\ll 90^\circ$ ) to accommodate faster signal recovery along with suitable signal correction methods has allowed much more rapid data acquisition.<sup>41</sup> For most biological samples, there is a substantial amount of water present, so strong solvent suppression must be employed to obtain good metabolite signals. Therefore, a 1D NOESY pulse sequence with water presaturation (see ref 42 and references therein), excitation sculpting,<sup>43</sup> or WATERGATE solvent suppression<sup>44</sup> is preferred. Because of solute/solvent hydrogen exchange, the presaturation sequence itself can dramatically alter quantitation results. Specifically, the exchangeable proton signals from urea and other water exchangeable solutes are often suppressed by presaturation, making their quantification difficult or inconsistent. While more complex solvent suppression schemes like PURGE,<sup>45</sup> excitation sculpting, or variations of WATERGATE<sup>46</sup> are potentially better choices for metabolite quantification, these pulse sequences all have auxiliary regions of signal suppression, which makes them more difficult to optimize and harder to use. This added complexity can also affect interlab and intralab consistency or reproducibility. Pulsed field gradient (PFG) versions of NMR pulse sequences (e.g., 1D NOESY pulse sequence) are available, but these may lead to problems with quantification due to both lock instability and gradient ring down periods.<sup>47</sup> These problems manifest as peak distortions (i.e., semidispersive line shape) to the internal chemical shift and quantitation reference (such as 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS)). For these reasons, gradient pulse sequences, despite their advantages,<sup>48</sup> are not recommended.

In terms of spectral analysis, metabolite quantification requires meticulous consistency and considerable attention to detail. Prior to spectral collection, each biofluid sample must be “spiked” with an exact amount of a known quantification standard (usually a chemical shift reference standard such as tetramethylsilane (TMS) for organic solvents or trimethylsilyl propanoic acid (TSP) and 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) for water-based experiments).<sup>49</sup> Once the NMR spectra have been collected, the data must be properly phased and baseline-corrected, and any residual interfering solvent signals must be digitally filtered. Then, individual “sentinel” peaks corresponding to the specific compounds must be identified, and the peak area(s) carefully integrated.<sup>50</sup> This identification and quantification step (also called spectral deconvolution) can be done manually, semiautomatically, or automatically (vide infra). The concentration of a given metabolite can be directly calculated from the spiked standard using the following formula<sup>51</sup>

$$\frac{[M]}{[\text{Std}]} = \frac{I_m}{I_s} \cdot \frac{N_m}{N_s} \quad (3)$$

where  $[M]$  is the metabolite molar concentration,  $[\text{Std}]$  is the spiked standard's known molar concentration,  $I_m$  is the metabolite intensity,  $I_s$  is the intensity of the spiked standard's peak,  $N_m$  is the number of nuclei contributing to the metabolite peak, and  $N_s$  is the number of nuclei contributing to the spiked standard's peak. In some cases it is not necessary to use an internal standard to quantify metabolites but rather one may use an external reference or an electronic reference signal,<sup>59,60</sup> or even the solvent resonances.<sup>52</sup>

A key challenge with quantifying metabolites in biological samples, and especially in urine, is the considerable degree of spectral overlap seen in 1D  $^1\text{H}$  NMR spectra. For example, urine NMR spectra typically consist of  $>2000$  detectable peaks corresponding to  $>200$  detectable compounds.<sup>53</sup> The positions and shapes of these peaks can vary with pH, temperature, salt concentrations, magnetic field strength, sample stability, and homogeneity. In addition, common  $^1\text{H}$ – $^1\text{H}$  dipolar or quadrupolar (e.g.,  $^{14}\text{N}$ – $^1\text{H}$ ) couplings further complicate the observations. Consequently, it is very difficult for even a trained individual to identify a single set of “sentinel” peaks that can be unambiguously identified and properly integrated for any given urine sample. To assist with this peak identification and metabolite identification process it is possible to use several approaches. One approach is spectral simplification through statistical analysis or chemometric analysis using spectral binning/alignment and statistical total correlation spectroscopy (STOCSY).<sup>54</sup> These methods statistically align and compare the NMR spectra between two groups (diseased and healthy), and the most significantly different peaks are then identified. This leads to a reduction in the number of peaks that need to be analyzed or identified. A disadvantage of this approach is that it can lead to problems in compound identification and quantification, as the spectra have been extensively averaged or “warped” as part of the statistical processing.<sup>54</sup>

Another approach involves identifying and quantifying as many compounds as possible prior to determining any statistical differences between groups. This leaves the NMR spectra in a relatively pristine state so that compound identification and quantification is easier and more accurate; however, the process is time-consuming, as dozens of compounds and hundreds of peaks must be identified and quantified through a process known as spectral deconvolution.<sup>54a</sup> Several companies have developed spectral deconvolution tools and software (e.g., Chenomx NMRSuite from Chenomx, Inc.; AMIX from Bruker, Inc.; MnovaScreen from Mestralab Research; CRAFT or Complete Reduction to Amplitude Frequency Table from Agilent) that makes this process easier. These packages include carefully collected reference NMR spectra of hundreds of common metabolites at different field strengths and pH values. These programs and their corresponding libraries can allow 50–75 compounds to be manually identified or quantified from urine spectra in about 1–4 h; however, this process must be performed by well-trained individuals. The requirements of manual phasing, manual baseline correction, manual solvent removal, and manual spectral deconvolution often mean that quantification inconsistencies and even compound identification errors can be introduced. For example, one published study looked into these issues of consistency and reproducibility<sup>39</sup> and found compound quantification by some of these methods is only accurate to within 15%. More recently several groups have attempted to develop fully automated methods that remove any human variability in spectral processing and compound identification.<sup>30b,55</sup> These methods appear to be very promising, especially for simpler biofluids such as serum, saliva, or cerebrospinal fluid, but they have yet to be shown to be effective for biofluids as complex as urine.

### Sample-to-Sample Normalization

The large differences in metabolite concentrations observed in different urine samples can complicate comparisons between samples and may lead to false conclusions. Thus, normalizing NMR spectra is a critical step for eliminating systematic errors.

In addition to normalizing concentrations relative to creatinine (which is commonly done in clinical practice), several other normalization methods have been developed, including total integral intensity (usually the total spectral area). This is one of the most commonly used methods in NMR.<sup>56</sup> Other methods have been proposed as an alternative to the total intensity method, including probabilistic quotient normalization (PQN)<sup>57</sup> and histogram matching (HM),<sup>58</sup> which effectively make the data more suitable to identifying potential metabolic biomarkers for disease.

Normalization can be problematic due to the potential influence that the method might have on compound identification or quantification. While one would hope that compound identification is unaffected (see later), the relative proportions certainly might. This assumes that normalization would occur only on the quantitation of unambiguous peaks (i.e., no overlap) and would apply to all such positively identified metabolites. This might seem obvious, but it needs to be explicitly stated as normalization can also refer to frequency-dependent compensation for NMR pulse sequence effects, for example,  $T_1$ -dependent changes. Any changes to the NMR pulse sequence or parameters will perturb peak heights. Any compensation for pulse sequence differences would also affect the peak ratios for atoms in the same molecule as well as the overall metabolite quantitation. For example, a compensation for different presaturation power levels would correct amplitudes differently close to the carrier position versus the edges of the spectra. A compound containing resonances both close to and far from the water resonance would then have an intramolecular integration ratio that would not make sense and could have its identification changed or moved to an ambiguous/unassigned grouping.

This is not a problem unique to NMR. Mass spectrometry (MS) has been dealing with this issue for years. In MS, control samples are introduced into the sample queue to compensate for changes in the chromatographic steps and equipment necessary to separate metabolites. Specifically, quality control samples are submitted at regular intervals or samples are combined and run as reference samples for comparison. Interestingly, in NMR, the use of control or calibration samples is not regularly done. While chromatographic columns are not normally used in NMR, batched samples run on robotic sample handling systems must often sit for lengthy periods of time (hours) prior to loading and spectral acquisition. Control samples placed at the beginning, middle, and end of a long sample-loading run would therefore reveal any potential degradation/storage/handling problems or (less likely) changes occurring to the spectrometer/console/probe.<sup>59</sup> Compared with the extensive efforts used in quality control for MS, the use of quality control for normalization in NMR is, in our opinion, still under-developed.

## 5. EXAMPLES OF POTENTIAL NMR-DERIVED URINARY BIOMARKERS

There is an abundance of literature linking urinary biomarkers with human disease states.<sup>7e,15b,60</sup> The analytical approaches used to collect these data are certainly diverse, and this diversity serves to demonstrate the complexity associated with developing standardized approaches for urinary biomarker quantification. Recently Bouatra et al.<sup>15a</sup> collated and critically evaluated the existing information on human urine to establish a comprehensive and electronically accessible human urine metabolome database (<http://www.urinemetabolome.ca>). This database includes quantitative concentrations of metabolites in normal and abnormal (i.e., disease-associated) urine samples and

represents a significant development and resource for biomarker identification and quantification. This database also serves as a benchmarking and cross-referencing tool for future metabolomics approaches and will no doubt aid in efforts aimed at standardizing metabolomic approaches. While it is impractical to cover all biomarker examples described in the human urine metabolome database, it is perhaps useful to highlight some of the studies where NMR-based metabolomics was used to identify novel or potentially important biomarkers in urine. These are summarized in Table 2 and explained in more detail below.

As can be seen in Table 2, urinary biomarkers have been identified for a wide range of conditions, ranging from cancer to neonatal conditions to pancreatic disorders. For example, Luszczyk and colleagues identified a useful set of potentially discriminating metabolites in the urine of pancreatitis patients compared with healthy controls.<sup>61</sup> Although the metabolites identified in this study cannot be conclusively defined as biomarkers of the disease, they do have the potential to become biomarkers once additional studies are carried out to validate their findings, ideally using a larger patient cohort. In a similar study aimed at exploring other kinds of pancreatic disorders, Davis et al. used NMR-based metabolomics investigation on urine samples from age- and gender-matched patients with pancreatic ductal adenocarcinoma, compared with a healthy control group.<sup>76</sup> These authors were able to easily differentiate between those with cancer and those in the control group (using both ROC curves and area under the curve [AUROC] calculations) using the set of strongly diagnostic metabolites listed in Table 2. As with the previous study, further validation using a larger cohort is needed to confirm the result. In another cancer-based study, urinary  $^1\text{H}$  NMR spectra of bladder cancer patients versus noncancer controls (healthy and those with urinary tract infections or bladder stones) were used to discriminate between the two groups, with taurine showing significant elevation in the urine of bladder cancer patients;<sup>62</sup> however, the authors of this study were not able to discriminate between different disease stages possibly due to cancer-specific metabolic alterations or the low sensitivity of their particular instrument.<sup>62</sup> Urinary biomarkers were also used to successfully and accurately diagnose a cohort West African patients with hepatocellular carcinoma.<sup>63</sup> In this particular study the authors not only calculated ROC and AUROC values, they actually validated their findings using second larger cohort, a very good practice indeed. The metabolite biomarker panel identified in this study was also shown to perform much better than serum alpha-fetoprotein, a protein biomarker that is traditionally used for hepatocellular carcinoma diagnosis.<sup>63</sup>

Another interesting set of studies highlighted in Table 2 concerns the application of NMR-based urinary metabolomics to neonatal diagnoses. One very interesting NMR-based study used urine samples from neonates to compare those with intrauterine growth retardation versus full-term normal-weight controls to better define the metabolic patterns associated with this pathology. The authors identified myo-inositol, sarcosine, creatine, and creatinine as key metabolites that clearly differentiated between the two groups.<sup>64</sup> While the initial findings are promising, the results will need to be further validated on a larger cohort. A more recent study on influence of early nutritional metabolic programming and long-term health in infants was carried out by Moltu et al. using NMR-based urinary metabolomics. In this intervention study, one group received significantly higher amounts of enhanced postnatal nutrition compared with the control group. We concluded that the

enhanced nutrition did not appear to affect the urinary profiles to an extent exceeding the individual variation.<sup>65</sup> This particular study is a good example of a well-conducted nutritional intervention study.

While the list of examples highlighted here (and in Table 2) is not exhaustive, it does highlight some of the common issues and challenges with respect to designing, implementing, and validating NMR-based urinary metabolomic biomarker studies. On the basis of these examples as well as an extensive review of the literature and a detailed assessment of the best practices conducted in our own laboratories and elsewhere, we have developed a set of consensus recommendations. These are summarized below.

## 6. RECOMMENDATIONS FOR SAMPLE COLLECTION AND PROCESSING

The identification of new biomarkers, along with their validation and translation into practical clinical applications, requires standardized preanalytical procedures for sample handling, sample stabilization, sample transport, and sample storage. Depending on the procedures employed, the detectable metabolites may be affected differentially by residual enzymatic activities or spontaneous chemical reactions that may alter the NMR profile.<sup>66</sup> These alterations could seriously bias the results of studies based on samples having different collection, treatment, and storage histories. Other factors that may affect the concentration levels of urine metabolites include drug administration, health conditions, diet, physical activities, and environmental stressors. Thus, it is crucial for any quantitative urinary analysis to standardize sample collection conditions. Our recommendations are as follows:

### Overnight Fasting

Overnight fasting prior to urine collection gives a more stable homeostatic picture of an individual's urinary metabolome. Consequently, we recommend that all urine samples should be collected the morning after overnight fasting to reduce the effects of diurnal variations.<sup>67</sup>

### Midstream Urine

Collecting midstream urine is recommended to avoid contamination from epithelial cells and bacteria from the urinary tract. Sampling conditions should be similar in control groups including age- and gender-matched groups for comparative analysis.

### Medical Procedures

Medical procedures (including drug intake) performed before sample collection should be recorded and properly taken into account as medical treatments could induce significant changes in metabolites levels. All medical procedures prior to sample collection should be reported.

### Aliquoting, Centrifugation, and Filtering Prior to Storage

Urine samples should be processed and aliquoted within 2 h from the time of collection but preferably faster. Samples must be kept refrigerated at 4 °C before processing and must not be frozen prior to processing to avoid possible cell breakage.<sup>20d</sup> Before aliquoting and long-term storage, urine samples should be centrifuged at 1000–3000 RCF (5 min at 4 °C) and (optionally) filtered using a 0.22 μm filter<sup>20d</sup> to remove cells and other particulates.

### Storage

For long-term storage, urine samples should be stored at –80 °C. If possible, for very long-term storage, it is better to use liquid

nitrogen vapor.<sup>20d</sup> Appropriately labeled cryovials should be used to store urine samples.

### Preservatives

The addition of micromolar quantities of inorganic bacteriostatic agents such as sodium azide (to limit bacterial growth) is appropriate. The use of externally added organic preservatives (such as EDTA or glycerol) is strongly discouraged due to their possible interference with metabolite signals.

### Diet Monitoring

Certain metabolites may be affected significantly by dietary intake. If possible, dietary information should be collected for 1 to 2 days before sampling. For example, taurine increases significantly after the consumption of taurine containing diet and energy drinks.<sup>68</sup> To reduce lifestyle-related variations, and to the extent experimental design allows, a standardized diet is recommended for donors at least 1 day before sample collection.

### Native Samples

Performing urine metabolomics on native (unadulterated, unprocessed) samples provides more reproducible and precise data. Extraction procedures, along with multistep sampling processes, increase the chance of metabolite loss. They also introduce analytical and operator errors.<sup>20d,69</sup>

### Buffering

An example basic protocol would be to mix 630 μL of human urine with 70 μL of phosphate buffer (prepared in <sup>2</sup>H<sub>2</sub>O) to minimize the drift in chemical shift due to pH variations. A concentrated KH<sub>2</sub>PO<sub>4</sub> solution (1.5 M, pH 7.0) is best. If the variation in pH between the samples is still significant after the addition of the phosphate buffer, sample pH may be adjusted by adding NaOH or HCl accordingly.<sup>15b</sup>

### Final Centrifugation

Centrifugation at 12 000g for at least 10 min at 4 °C to remove any suspended particles is strongly encouraged.<sup>20d</sup>

### Chemical Shift Referencing

A chemical shift referencing standard such as TSP or DSS should always be added prior to NMR collection. Because the peak is easily resolved and unique, chemical shift standards can also be used for metabolite quantification. Note that DSS and TSP do bind proteins and lipids, so if these macromolecules are present to any significant degree, they may give rise to errors in quantitation. A final TSP or DSS concentration ranging between 0.1 and 0.5 mM is sufficient for most urine samples.

## 7. RECOMMENDATIONS FOR SPECTRAL ACQUISITION AND PROCESSING

In addition to the recommendations for spectral acquisition that have been proposed in our previous reference paper,<sup>22</sup> there are a number of instrumental, acquisition, and data-processing parameters that can significantly affect quantitative accuracy and precision. These parameters need to be optimized prior to conducting quantitative analysis of urine samples. Here we provide recommendations and justifications related to these issues.

### 7.1. Acquisition of Urinary NMR Data

**Selection of Magnetic Field.** NMR-based metabolomics studies on urine benefit from the use of the highest accessible magnetic field strengths. Presently, most NMR-based metabolomic studies are conducted using 600 MHz NMR spectrometers, as these instruments are relatively abundant and offer a

good compromise between the cost, sensitivity, and resolution needed for metabolomics experiments. If the purpose of the analysis is the quantification or the identification of low abundance metabolites, we recommend using more sophisticated 2D experiments, higher fields (e.g., 800–1000 MHz), or increased sensitivity “cold-probes” or “cryoprobes”.

**Pulse Sequence and General Setup.** Automated pulse width calibration<sup>70</sup> is strongly recommended for any NMR-based metabolomic study of urine. This is because urine samples exhibit considerable variability in salt concentrations, which substantially affect pulse widths. Pulse width calibration also helps to compensate for differences in sample volume or drift/decay in NMR hardware performance. For example, if components of the spectrometer or probe begin to fail, then pulse width calibrations will immediately indicate a problem and prevent wasted time and resources. Most modern NMR spectrometers have the option of sample handling robots for sample insertion into the spectrometer. Most NMR instruments also support autopulse calibration, autoshim, and auto tune/match prior to data acquisition. If available, these automated approaches should be used for all urine-based metabolomics studies to reduce human error and ensure maximum consistency and reproducibility.

**Water Suppression.** As previously detailed, a 1D NOESY pulse sequence with water presaturation, is the most commonly used NMR pulse sequence for metabolomics studies. While there are other excellent solvent suppression techniques such as excitation sculpting, or WATERGATE, the incorporation of pulsed field gradients can easily result in inconsistent spectrometer lock performance, the introduction of artifacts, and irreproducible solvent suppression; however, a presaturation pulse if done inconsistently, can also dramatically alter quantitation results due to hydrogen exchange with the solvent during the long saturation period(s).<sup>71</sup> We therefore strongly recommend the use of an absolutely consistent presaturation period (e.g., 1 s) with equally consistently delivered and calibrated power (e.g., 80 Hz gamma B<sub>1</sub> induced field). Of note, the exchangeable hydrogen signal from urea's NH<sub>2</sub>- groups and other water exchangeable signals can also be suppressed by time-shared multifrequency saturation-based sequences,<sup>72</sup> but these also introduce additional regions of suppression that can alter quantitation. Therefore, these types of sequences are not recommended for metabolomics.

**Sample Temperature Control.** Variations in the sample temperature during spectral acquisition can significantly affect the precision and reproducibility of NMR data. A calibrated sample temperature of ~298 K (25 °C) for urine is recommended during NMR spectral acquisition. If a robotic sample handling system is being used, where large numbers of samples are prepared in advance and stored at the instrument, the samples should be kept below room temperature (~5 °C) while waiting for sample insertion.<sup>29a,73</sup> Samples should be prewarmed outside or in the probe for 5–10 min before spectral acquisition to ensure proper temperature equilibration, especially if a cooling rack is used to maintain refrigerated samples. While samples will begin to show thermal equilibrium via lock monitoring in 60 to 120 s, several minutes of equilibration are often necessary for convection currents to settle.

**NMR Tubes.** Higher quality NMR tubes yield higher quality spectra. Therefore, we recommend that the highest quality tubes with the lowest camber (straightest), thinnest, most consistent glass wall widths be used. Slightly curved tubes will wobble while spinning, which can lead to spinning side bands (extra peaks). Most NMR spectroscopists use 5 mm tubes, requiring volumes

of 400–600  $\mu$ L of material. If less material is available, the use of 3 mm or even 1.7 mm tubes is possible. Likewise, solvent-matched (Shigemi) tubes may also be used for low volume situations; however this option can increase the cost significantly. Prior to their use, NMR tubes should be cleaned to remove any film. Cleaned tubes tend to sheet refluxed material back down into the bottom of the tube, thus reaching equilibrium faster. Dirty or stock tubes with the film remaining from manufacturing will bead solvent further up the tube, effectively shortening the sample length and changing the magnetic field homogeneity.

## 7.2. Recommendations for Optimized Instrumental Parameters

**Time Domain Points (Bruker TD or Agilent np).** Modern NMR spectrometers with high-speed/high-memory computers and digital oversampling can easily collect 64K or more data points. Considering the expected spectral windows and the desired resolution for NMR-based metabolomics work, time domain acquisitions  $\geq 32$ K points are recommended for quantitative analysis of urine samples.

**Repetition Time ( $T_R$ ).** This is also known as the relaxation delay or waiting period prior to the first hard excitation pulse. We define this period as the total time spent in acquiring a single scan spectrum, including the acquisition time and acquisition delays prior to the next excitation/acquisition. This period strongly affects the absolute quantitation of metabolites. Ideally,  $T_R$  should be five times the longest  $T_1$  in the sample. This typically provides enough time for complete relaxation of all resonances between every scan, resulting in good quantitation. In metabolomics studies, using a  $T_R$  that is five times the longest  $T_1$  in a sample requiring 128 scans would result in a sacrifice of enormous amounts of instrumental time that would dramatically increase the cost of the overall study. As a result, a shorter repetition time (e.g., 2–4 s) is often used for many NMR studies.<sup>69</sup> The key is that the total relaxation time used is consistent from experiment to experiment. For absolute quantitation of metabolites, a  $T_1$  correction factor for spectra recorded over a shorter  $T_R$  time can be determined and applied to compensate for the effect of incomplete relaxation.<sup>74</sup> Application of this correction requires evaluation of the  $T_1$  for all resonances of interest in a representative sample prior to quantitation, assuming that the  $T_1$  of the resonances would be the same in all samples for the study. Alternately, using reference spectra of compounds of known concentration that have been collected using the same TR and using these reference spectra to deconvolute the mixture (as done with Chenomx, AMIX, Batman, or Bayesil) would also allow one to accurately determine concentrations.

**Number of Scans/Signal to Noise Ratio.** The better the signal-to-noise (S/N) is for a NMR spectrum, the more reliable the absolute quantitation. The simplest way to increase (S/N) in NMR is to increase the number of scans (also known as transients); however, adding more scans must be balanced by cost or time considerations. The S/N also depends on other factors like the magnetic field strength, stability of the spectrometer, probe type/quality, sample concentration, sample volume, excitation flip angle, and so on. If time and resources permit, maximizing each of these factors (field strength, stability, probe quality, sample concentration, sample volume, and flip angle) will yield significant gains in S/N without the need for additional acquisition time. Thirty-two to sixty-four scans are often considered enough for a normal urine sample on a 600 MHz (or greater field strength) instrument. Dilute urine will

require more scans to achieve the desired S/N for quantitative NMR analysis. More scans (or higher fields) are also required to detect and quantify minor components (<10  $\mu\text{M}$ ) in urine or very dilute samples. Use of a cryogenically cooled probe can significantly (by a factor of 2–4 times) increase the S/N for the sample.

**Receiver Gain (RG).** NMR experiments can be run either on a constant receiver gain setting (optimized to a standard sample) or with an automatically optimized receiver gain for every sample. The former is preferred for pattern recognition analysis of urine NMR data; however, it does not work on samples where concentration variation between samples is substantial. In these cases the auto receiver gain setting may be required for every sample prior to acquisition, or an efficiently low gain would be required.

**Shimming.** Automatic shimming options in newer NMR spectrometers have made shimming much easier and faster for metabolomic analysis. NMR shims can be optimized by watching the line shape and width at half-height of the reference signal (such as DSS or TSP) or another common low-molecular-weight component. For DSS/TSP, observing the intensity and symmetry of the silicon ( $^{29}\text{Si}$ ) satellite signal is also a good option to optimize the shimming process. The line width of chemical shift standards such as DSS or TSP should be shimmed to between 0.5 and 1.0 Hz. Adjustment of the field and lock position/phase during the shimming process can also improve the quality of the spectra.

**Tuning and Matching.** Probe tuning and matching (which is equivalent to tuning a radio) are essential to getting high-quality NMR spectra. Many NMR instruments are tuned for salt-free solvents (chloroform or  $\text{D}_2\text{O}$ ); however, buffered urine samples typically have high salt concentrations. This can lead to poor performance (low S/N, long pulses, poor solvent suppression, etc.) on high-field NMR spectrometers that have not previously been tuned to accommodate high salt samples. These difficulties can become more evident when a user is acquiring data on a cryogenically cooled NMR probe. Ideally, manual probe tuning and matching for a given sample or solvent type (using a representative sample) should be performed prior to spectral acquisition for a large number of solvent-similar samples. Autotune capabilities and match accessories along with salt tolerant NMR flat sample tubes can help mitigate this problem.

### 7.3. Data Processing

Proper data processing can improve the S/N, resolution, visual appearance, and the integration accuracy of 1D NMR spectra. Several simple data processing techniques may be employed, some of which are automatic while others require some manual effort and skill. Our recommendations are as follows:

**Windowing or Apodization.** A window function should be applied to the time domain data prior to Fourier transformation to improve the appearance of the spectra and emphasize either S/N or resolution (both are not possible). In a urine 1D spectrum, a free induction decay (FID) can be multiplied by an exponential window function. The artificially increased decay rate of an exponential windowing function (which minimizes later time points in the FID) will reduce the noise and broaden the resonance lines. On the contrary, a window function that enhances later time points in the FID will enhance resolution but at the expense of increasing spectral noise. Line broadening between 0.3 and 1.0 Hz is recommended for quantitative analysis of urine samples. The exact value will depend on the digital

resolution of the experiment. Line broadening equal to the digital resolution is generally recommended, as it provides no penalty in spectral separation but does improve general spectral appearance.

**Zero Filling.** FID data should be zero-filled by a factor of 2 (i.e., twice the number of experimentally collected data points) before Fourier transformation to reduce noise and improve the visual appearance of the spectra. Zero filling does not increase the actual spectral resolution but functions to better interpolate between real data points in the original spectrum, thereby improving line-fitting and peak position determination. While often over emphasized, zero filling is still helpful for many NMR spectroscopists and does not require additional spectrometer time. Extending zero filling past a factor of 2 does little for the spectra, takes up more storage space, and slows software calculations.

**Phasing.** Phasing is one of the most critical yet one of the more error-prone steps in performing quantitative NMR. Errors in phasing can cause significant errors in absolute and relative peak area measurements.<sup>75</sup> Manual phasing is preferred over automatic phasing because there is a greater chance of distortion among lower intensity signals during automatic phase correction. Vertical expansion should be increased as much as possible during manual phasing to make the proper adjustments for smaller signals. Water peaks can be ignored during phasing, and the water signal should be removed (through postprocessing digital filtration) from the spectra to enable further qualitative and quantitative analysis. Experimental errors in the pulse sequence can often manifest as apparent “phase” distortions but cannot be corrected with either frequency-dependent or frequency-independent corrections. Dispersive peak characteristics, especially on very intense peaks, should be carefully examined and noted in case the NMR parameters/setup need to be altered.

**Base Line Correction.** Proper baseline corrections are necessary for quantitative accuracy of peak integration and curve-fitting methods applied to calculate peak areas. Most baseline corrections are performed semiautomatically through manual identification of baseline regions, followed by a computer-generated spline fit to the baseline regions. Several third-party software packages can also perform automated baseline correction.<sup>50</sup>

**Chemical Shift Referencing.** Every spectrum needs to be properly referenced to an internal chemical shift standard before qualitative/quantitative analysis. In many cases, because the precise concentration of the standard is known, the chemical shift standard can also be used to determine the concentration of other compounds by comparing the relative peak areas. Both trimethylsilyl propanoic acid (TSP) and 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) can be used for chemical shift referencing in water ( $\delta$  0.0), although DSS is the IUPAC standard. While other peaks may be used in place of an internal standard if they are very insensitive to pH/ionic strength variations, this practice is definitely not recommended for most applications (water has been successfully used as a concentration reference).<sup>52</sup> Chemical shift referencing to solvent peaks (i.e., water) should be avoided because its peak position is sensitive to pH, salt, and temperature effects.

## ■ CONCLUDING REMARKS

Despite the growing number of publications focused on diagnostic metabolite biomarkers appearing in the scientific literature, a surprisingly small number of these reports provide

information on quantified metabolite levels, especially in urine. This situation indicates that metabolite identification and quantification in urine is still considered a challenging task. For metabolite biomarkers, accurate identification and quantification is essential for advancing biomarker discoveries to clinical practice. As noted throughout this review, NMR spectroscopy offers a robust route to the identification and quantification of metabolites. In this regard, we believe quantitative NMR-based metabolomics represents a superb (albeit under-used) platform for the discovery, development, and translation of metabolite biomarkers to clinical practice. In this Review, we focused on the use of urine as a biofluid for biomarker discovery and biomarker applications. In particular, we explained how biomarkers should be evaluated or assessed. We also elaborated on several methods for metabolite identification, quantification and normalization by NMR and provided examples of a number of newly discovered urinary metabolite biomarkers. We further discussed a number of the most significant issues or challenges regarding the experimental aspects of quantitative, NMR-based urinary metabolomics. To address these experimental challenges, several consensus recommendations were provided. These included best-practice recommendations regarding: (1) sample collection, (2) sample processing and storage, (3) NMR data acquisition, and (4) NMR instrument setup and NMR data processing. Detailed justifications were provided for each of these recommendations. We believe that if these recommendations are followed, they will help members of the NMR metabolomics community better validate and translate their biomarker discoveries from the lab into clinical practice.

## AUTHOR INFORMATION

### Corresponding Author

\*Tel: +966-2-8084313. Mobile: +966-544700331. E-mail: [abdelhamid.emwas@kaust.edu.sa](mailto:abdelhamid.emwas@kaust.edu.sa).

### Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

We thank Dr. Virginia Unkefer from KAUST for her assistance and helpful remarks. This work was supported by King Abdullah University of Science and Technology (KAUST). Funding for this work from the NIH (R01GM085291) is gratefully acknowledged and European Commission (FP 7) COSMOS Grant EC312941.

## REFERENCES

(1) (a) Al-Talla, Z. A.; Akrawi, S. H.; Emwas, A. H. M. Solid state NMR and bioequivalence comparison of the pharmacokinetic parameters of two formulations of clindamycin. *Int. J. Clin. Pharmacol. Ther.* **2011**, *49* (7), 469–476. (b) Al-Talla, Z. A.; Akrawi, S. H.; Tolley, L. T.; Sioud, S. H.; Zaater, M. F.; Emwas, A. H. Bioequivalence assessment of two formulations of ibuprofen. *Drug Des., Dev. Ther.* **2011**, *5*, 427–33. (c) Li, J.; Wang, S.; Wang, M.; Shi, W.; Du, X.; Sun, C. The toxicity of 3-chloropropane-1,2-dipalmitate in Wistar rats and a metabolomics analysis of rat urine by ultra-performance liquid chromatography-mass spectrometry. *Chem.-Biol. Interact.* **2013**, *206* (2), 337–345. (d) Nie, C. Y.; Han, T.; Zhang, L.; Li, Y.; Liu, H.; Xiao, S. X.; Li, Y.; Kang, H.; Liu, S. Y. Cross-sectional and dynamic change of serum metabolite profiling for Hepatitis B-related acute-on-chronic liver failure by UPLC/MS. *Journal of Viral Hepatitis* **2014**, *21* (1), 53–63. (e) Szultka, M.; Krzeminski, R.; Walczak, J.; Jackowski, M.; Buszewski, B. Pharmacokinetic study of amoxicillin in human plasma by solid-phase microextraction followed by

high-performance liquid chromatography-triple quadrupole mass spectrometry. *Biomed. Chromatogr.* **2014**, *28* (2), 255–264. (f) Lan, K.; Zhang, Y.; Yang, J.; Xu, L. Simple quality assessment approach for herbal extracts using high performance liquid chromatography-UV based metabolomics platform. *Journal of Chromatography A* **2010**, *1217* (8), 1414–1418. (g) Liang, X.; Zhang, L.; Zhang, X.; Dai, W.; Li, H.; Hu, L.; Liu, H.; Su, J.; Zhang, W. Qualitative and quantitative analysis of traditional Chinese medicine Niu Huang Jie Du Pill using ultra performance liquid chromatography coupled with tunable UV detector and rapid resolution liquid chromatography coupled with time-of-flight tandem mass spectrometry. *J. Pharm. Biomed. Anal.* **2010**, *51* (3), 565–571. (h) Zheng, S.; Yu, M.; Lu, X.; Huo, T.; Ge, L.; Yang, J.; Wu, C.; Li, F. Urinary metabolomic study on biochemical changes in chronic unpredictable mild stress model of depression. *Clin. Chim. Acta* **2010**, *411* (3–4), 204–209.

(2) (a) Ciborowski, M.; Lipska, A.; Godzien, J.; Ferrarini, A.; Korsak, J.; Radziwon, P.; Tomasiak, M.; Barbas, C. Combination of LC-MS- and GC-MS-based Metabolomics to Study the Effect of Ozonated Autohemotherapy on Human Blood. *J. Proteome Res.* **2012**, *11* (12), 6231–6241. (b) Liu, M.-L.; Zheng, P.; Liu, Z.; Xu, Y.; Mu, J.; Guo, J.; Huang, T.; Meng, H.-Q.; Xie, P. GC-MS based metabolomics identification of possible novel biomarkers for schizophrenia in peripheral blood mononuclear cells. *Mol. BioSyst.* **2014**, *10* (9), 2398–2406. (c) Raji, M.; Amad, M.; Emwas, A. H. Dehydrodimerization of pterostilbene during electrospray ionization mass spectrometry. *Rapid Commun. Mass Spectrom.* **2013**, *27* (11), 1260–6.

(3) (a) Emwas, A.-H. M.; Al-Talla, Z. A.; Kharbatia, N. M. Sample collection and preparation of biofluids and extracts for gas chromatography-mass spectrometry. *Methods Mol. Biol. (N. Y., NY, U. S.)* **2015**, *1277*, 75–90. (b) Emwas, A.-H. M.; Al-Talla, Z. A.; Yang, Y.; Kharbatia, N. M. Gas chromatography-mass spectrometry of biofluids and extracts. *Methods Mol. Biol. (N. Y., NY, U. S.)* **2015**, *1277*, 91–112.

(4) (a) Guo, J.; Zhang, M.; Elmore, C. S.; Vishwanathan, K. An integrated strategy for in vivo metabolite profiling using high-resolution mass spectrometry based data processing techniques. *Anal. Chim. Acta* **2013**, *780*, 55–64. (b) Huang, Y.; Tian, Y.; Li, G.; Li, Y.; Yin, X.; Peng, C.; Xu, F.; Zhang, Z. Discovery of safety biomarkers for realgar in rat urine using UFLC-IT-TOF/MS and H-1 NMR based metabolomics. *Anal. Bioanal. Chem.* **2013**, *405* (14), 4811–4822. (c) Vadla, N. C.; Davalagar, V. D.; Sripadi, P. Detection and characterization of N-alkyl diethanolamines and N-2-alkoxyethyl diethanolamines in milk by electrospray ionization mass spectrometry. *Metabolomics* **2013**, *9* (3), 623–630. (d) Allard, E.; Backstrom, D.; Danielsson, R.; Sjoberg, J. R.; Bergquist, J. Comparing Capillary Electrophoresis - Mass Spectrometry Fingerprints of Urine Samples Obtained after Intake of Coffee, Tea, or Water. *Anal. Chem.* **2008**, *80* (23), 8946–8955. (e) Chen, Y.-H.; Chen, C.-H.; Lin, C.-J.; Chen, C.-C. Metabonomic Study with a High Performance Liquid Chromatography Coupling to a Triple Quadrupole Mass Spectrometer to Identify Biomarkers from Urine of High-fat Fed and Streptozotocin Treated Rats. *J. Food Drug Anal.* **2009**, *17* (1), 28–35. (f) Cho, S.-H.; Choi, M. H.; Kwon, O. S.; Lee, W.-Y.; Chung, B. C. Metabolic significance of bisphenol A-induced oxidative stress in rat urine measured by liquid chromatography-mass spectrometry. *J. Appl. Toxicol.* **2009**, *29* (2), 110–117.

(5) (a) Kim, J. W.; Ryu, S. H.; Kim, S.; Lee, H. W.; Lim, M.-s.; Seong, S. J.; Kim, S.; Yoon, Y.-R.; Kim, K.-B. Pattern Recognition Analysis for Hepatotoxicity Induced by Acetaminophen Using Plasma and Urinary H-1 NMR-Based Metabolomics in Humans. *Anal. Chem.* **2013**, *85* (23), 11326–11334. (b) Wang, B.; Goodpaster, A. M.; Kennedy, M. A. Coefficient of variation, signal-to-noise ratio, and effects of normalization in validation of biomarkers from NMR-based metabolomics studies. *Chemom. Intell. Lab. Syst.* **2013**, *128*, 9–16. (c) He, C.-C.; Dai, Y.-Q.; Hui, R.-R.; Hua, J.; Chen, H.-J.; Luo, Q.-Y.; Li, J.-X. NMR-based metabolomic approach on the toxicological effects of a Cimicifuga triterpenoid. *J. Appl. Toxicol.* **2012**, *32* (2), 88–97. (d) Calvani, R.; Miccheli, A.; Capuani, G.; Miccheli, A. T.; Puccetti, C.; Delfini, M.; Iaconelli, A.; Nanni, G.; Mingrone, G. Gut microbiome-derived metabolites characterize a peculiar obese urinary metabolite. *Int. J. Obes.* **2010**, *34* (6), 1095–1098. (e) Liu, Y.; Huang, R.; Liu, L.; Peng, J.;

Xiao, B.; Yang, J.; Miao, Z.; Huang, H. Metabonomics study of urine from Sprague-Dawley rats exposed to Huang-yao-zi using H-1 NMR spectroscopy. *J. Pharm. Biomed. Anal.* **2010**, *52* (1), 136–141. (f) Zhang, S.; Nagana Gowda, G. A.; Ye, T.; Raftery, D. Advances in NMR-based biofluid analysis and metabolite profiling. *Analyst* **2010**, *135* (7), 1490–1498. (g) Wishart, D. S. Quantitative metabolomics using NMR. *TrAC, Trends Anal. Chem.* **2008**, *27* (3), 228–237. (h) Zhang, S.; Nagana Gowda, G. A.; Asiago, V.; Shanaiah, N.; Barbas, C.; Raftery, D. Correlative and quantitative H-1 NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats. *Anal. Biochem.* **2008**, *383* (1), 76–84.

(6) Emwas, A.-H. M. The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research. *Methods Mol. Biol. (N. Y., NY, U. S.)* **2015**, *1277*, 161–93.

(7) (c) Smolinska, A.; Blanchet, L.; Buydens, L. M. C.; Wijmenga, S. S. NMR and pattern recognition methods in metabolomics: From data acquisition to biomarker discovery: A review. *Anal. Chim. Acta* **2012**, *750*, 82–97. (d) Heather, L. C.; Wang, X.; West, J. A.; Griffin, J. L. A practical guide to metabolomic profiling as a discovery tool for human heart disease. *J. Mol. Cell. Cardiol.* **2013**, *55*, 2–11. (e) Wei, R. Metabolomics and Its Practical Value in Pharmaceutical Industry. *Curr. Drug Metab.* **2011**, *12* (4), 345–358. (f) Zulyniak, M. A.; Mutch, D. M. Harnessing Metabolomics for Nutrition Research. *Curr. Pharm. Biotechnol.* **2011**, *12* (7), 1005–1015. (g) Nageeb, A.; Al-Tawashi, A.; Emwas, A.-H.; Al-Talla, Z.; Al-Rifai, N. Comparison of Artemisia annua Bioactivities between Traditional Medicine and Chemical Extracts. *Curr. Bioact. Compd.* **2014**, *9* (4), 324–332. (a) Emwas, A.-H. M.; Antakly, T.; Saoudi, A.-H.; Al-Ghamdi, S.; Serai, H. Magnetic Resonance Spectroscopy and Imaging in Breast Cancer Prognosis and Diagnosis. *Applications of NMR Spectroscopy* **2015**, *3*, 4–35. (b) Emwas, A.-H. M.; Merzaban, J. S.; Serrai, H.; Atta-ur-Rahman, M. I. C. Theory and Applications of NMR-Based Metabolomics in Human Disease Diagnosis. *Applications of NMR Spectroscopy* **2015**, *1*, 93–130.

(8) Aimetti, M.; Cacciatore, S.; Graziano, A.; Tenori, L. Metabonomic analysis of saliva reveals generalized chronic periodontitis signature. *Metabolomics* **2012**, *8* (3), 465–474.

(9) Wishart, D. S.; Lewis, M. J.; Morrissey, J. A.; Flegel, M. D.; Jeronic, K.; Xiong, Y.; Cheng, D.; Eisner, R.; Gautam, B.; Tzur, D.; Sawhney, S.; Bamforth, F.; Greiner, R.; Li, L. The human cerebrospinal fluid metabolome. *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.* **2008**, *871* (2), 164–173.

(10) Graca, G.; Duarte, I. F.; Goodfellow, B. J.; Carreira, I. M.; Couceiro, A. B.; Domingues, M. d. R.; Spraul, M.; Tseng, L.-H.; Gil, A. M. Metabolite profiling of human amniotic fluid by hyphenated nuclear magnetic resonance spectroscopy. *Anal. Chem.* **2008**, *80* (15), 6085–6092.

(11) Lacitignola, L.; Fanizzi, F. P.; Francioso, E.; Crovace, A. H-1 NMR investigation of normal and osteoarthritic synovial fluid in the horse. *Veterinary and Comparative Orthopaedics and Traumatology* **2008**, *21* (1), 85–88.

(12) Bertini, I.; Luchinat, C.; Miniati, M.; Monti, S.; Tenori, L. Phenotyping COPD by H-1 NMR metabolomics of exhaled breath condensate. *Metabolomics* **2014**, *10* (2), 302–311.

(13) Bertini, I.; Hu, X.; Luchinat, C. Global metabolomics characterization of bacteria: pre-analytical treatments and profiling. *Metabolomics* **2014**, *10* (2), 241–249.

(14) Cacciatore, S.; Hu, X.; Viertler, C.; Kap, M.; Bernhardt, G. A.; Mischinger, H.-J.; Riegman, P.; Zatloukal, K.; Luchinat, C.; Turano, P. Effects of Intra- and Post-Operative Ischemia on the Metabolic Profile of Clinical Liver Tissue Specimens Monitored by NMR. *J. Proteome Res.* **2013**, *12* (12), 5723–5729.

(15) (a) Bouatra, S.; Aziat, F.; Mandal, R.; Guo, A. C.; Wilson, M. R.; Knox, C.; Bjorn Dahl, T. C.; Krishnamurthy, R.; Saleem, F.; Liu, P.; Dame, Z. T.; Poelzer, J.; Huynh, J.; Yallou, F. S.; Psychogios, N.; Dong, E.; Bogumil, R.; Roehring, C.; Wishart, D. S. The Human Urine Metabolome. *PLoS One* **2013**, *8* (9), e73076. (b) Emwas, A.-H. M.; Salek, R. M.; Griffin, J. L.; Merzaban, J. NMR-based metabolomics in

human disease diagnosis: applications, limitations, and recommendations. *Metabolomics* **2013**, *9* (5), 1048–1072.

(16) (a) Assfalg, M.; Bertini, I.; Colangioli, D.; Luchinat, C.; Schaefer, H.; Schuetz, B.; Spraul, M. Evidence of different metabolic phenotypes in humans. *Proc. Natl. Acad. Sci. U. S. A.* **2008**, *105* (5), 1420–1424. (b) Bernini, P.; Bertini, I.; Luchinat, C.; Nepi, S.; Saccenti, E.; Schaefer, H.; Schuetz, B.; Spraul, M.; Tenori, L. Individual Human Phenotypes in Metabolic Space and Time. *J. Proteome Res.* **2009**, *8* (9), 4264–4271.

(17) Travagli, V.; Zanardi, I.; Bernini, P.; Nepi, S.; Tenori, L.; Bocci, V. Effects of Ozone Blood Treatment on the Metabolite Profile of Human Blood. *Int. J. Toxicol.* **2010**, *29* (2), 165–174.

(18) Ryan, D.; Robards, K.; Prenzler, P. D.; Kendall, M. Recent and potential developments in the analysis of urine: A review. *Anal. Chim. Acta* **2011**, *684* (1–2), 17–29.

(19) Pinto, J.; Domingues, M. R. M.; Galhano, E.; Pita, C.; Almeida, M. d. C.; Carreira, I. M.; Gil, A. M. Human plasma stability during handling and storage: impact on NMR metabolomics. *Analyst* **2014**, *139* (5), 1168–1177.

(20) (a) Abriata, L. A. Utilization of NMR spectroscopy to study biological fluids and metabolic processes: Two introductory activities. *Concepts Magn. Reson., Part A* **2012**, *40A* (4), 171–178. (b) Beckonert, O.; Keun, H. C.; Ebbels, T. M. D.; Bundy, J. G.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. *Nat. Protoc.* **2007**, *2* (11), 2692–2703. (c) Beltran, A.; Suarez, M.; Rodriguez, M. A.; Vinaixa, M.; Samino, S.; Arola, L.; Correig, X.; Yanes, O. Assessment of Compatibility between Extraction Methods for NMR- and LC/MS-Based Metabolomics. *Anal. Chem.* **2012**, *84* (14), 5838–5844. (d) Bernini, P.; Bertini, I.; Luchinat, C.; Nincheri, P.; Staderini, S.; Turano, P. Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks. *J. Biomol. NMR* **2011**, *49* (3–4), 231–243. (e) Bingol, K.; Brueschweiler, R. Multidimensional Approaches to NMR-Based Metabolomics. *Anal. Chem.* **2014**, *86* (1), 47–57. (f) Foxall, P. J. D.; Spraul, M.; Farrant, R. D.; Lindon, L. C.; Neild, G. H.; Nicholson, J. K. 750 MHz 1H-NMR spectroscopy of human blood plasma. *J. Pharm. Biomed. Anal.* **1993**, *11* (4–5), 267–276. (g) Garde, A. H.; Hansen, A. M.; Kristiansen, J.; Knudsen, L. E. Comparison of uncertainties related to standardization of urine samples with volume and creatinine concentration. *Ann. Occup. Hyg.* **2004**, *48* (2), 171–179.

(21) Fiehn, O.; Robertson, D.; Griffin, J.; van der Werf, M.; Nikolau, B.; Morrison, N.; Sumner, L. W.; Goodacre, R.; Hardy, N. W.; Taylor, C.; Fostel, J.; Kristal, B.; Kaddurah-Daouk, R.; Mendes, P.; van Ommen, B.; Lindon, J. C.; Sansone, S.-A. The metabolomics standards initiative (MSI). *Metabolomics* **2007**, *3* (3), 175–178.

(22) Emwas, A.-H.; Luchinat, C.; Turano, P.; Tenori, L.; Roy, R.; Salek, R. M.; Ryan, D.; Merzaban, J. S.; Kaddurah-Daouk, R.; Zeri, A. C.; Gowda, G. A. N.; Raftery, D.; Wang, Y.; Brennan, L.; Wishart, D. S. Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. *Metabolomics* **2015**, *11* (4), 872–894.

(23) Xia, J.; Broadhurst, D. I.; Wilson, M.; Wishart, D. S. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. *Metabolomics* **2013**, *9* (2), 280–299.

(24) Garrod, A. E. The croonian lectures on inborn errors of metabolism. *Lancet* **1908**, *172* (4427), 1–7.

(25) Marshall, S. L.; Edidin, D. V.; Arena, V. C.; Becker, D. J.; Bunker, C. H.; Gishoma, C.; Gishoma, F.; LaPorte, R. E.; Kaberuka, V.; Ogle, G.; Sibomana, L.; Orchard, T. J. Glucose control in Rwandan youth with type 1 diabetes following establishment of systematic, HbA1c based, care and education. *Diabetes Res. Clin. Pract.* **2015**, *107* (1), 113–122.

(26) Nephro Test Study Group. Decrease in Urinary Creatinine Excretion in Early Stage Chronic Kidney Disease. *PLoS One* **2014**, *9* (11), e111949.

(27) Silberring, J.; Ciborowski, P. Biomarker discovery and clinical proteomics. *TrAC, Trends Anal. Chem.* **2010**, *29* (2), 128–140.

(28) Nagana Gowda, G. A.; Gowda, Y. N.; Raftery, D. Expanding the limits of human blood metabolite quantitation using NMR spectroscopy. *Anal. Chem.* **2015**, *87* (1), 706–15.

- (29) (a) Saude, E. J.; Adamko, D.; Rowe, B. H.; Marrie, T.; Sykes, B. D. Variation of metabolites in normal human urine. *Metabolomics* **2007**, *3* (4), 439–451. (b) Schnackenberg, L. K.; Sun, J.; Espandiari, P.; Holland, R. D.; Hanig, J.; Beger, R. D. Metabonomics evaluations of age-related changes in the urinary compositions of male Sprague Dawley rats and effects of data normalization methods on statistical and quantitative analysis. *BMC Bioinf.* **2007**, *8*, S3.
- (30) (a) Hao, J.; Liebeke, M.; Astle, W.; De Iorio, M.; Bundy, J. G.; Ebbels, T. M. D. Bayesian deconvolution and quantification of metabolites in complex 1D NMR spectra using BATMAN. *Nat. Protoc.* **2014**, *9* (6), 1416–1427. (b) Hao, J.; Astle, W.; De Iorio, M.; Ebbels, T. M. D. BATMAN-an R package for the automated quantification of metabolites from nuclear magnetic resonance spectra using a Bayesian model. *Bioinformatics* **2012**, *28* (15), 2088–2090.
- (31) Ravanbakhsh, S.; Liu, P.; Bjordahl, T. C.; Mandal, R.; Grant, J. R.; Wilson, M.; Eisner, R.; Sinelnikov, I.; Hu, X.; Luchinat, C.; Greiner, R.; Wishart, D. S. Accurate, Fully-Automated NMR Spectral Profiling for Metabolomics. *PLoS One* **2015**, *10* (5), e0124219.
- (32) (a) Abuhijleh, A. L.; Abu Ali, H.; Emwas, A.-H. Synthesis, spectral and structural characterization of dinuclear rhodium (II) complexes of the anticonvulsant drug valproate with theophylline and caffeine. *J. Organomet. Chem.* **2009**, *694* (22), 3590–3596. (b) Blindauer, C. A.; Emwas, A. H.; Holy, A.; Dvorakova, H.; Sletten, E.; Sigel, H. Complex formation of the antiviral 9- 2-(phosphonomethoxy)ethyl adenine (PMEA) and of its N1, N3, and N7 deaza derivatives with copper(II) in aqueous solution. *Chem. - Eur. J.* **1997**, *3* (9), 1526–1536. (c) Di Gangi, I. M.; Vrhovsek, U.; Paziienza, V.; Mattivi, F. Analytical metabolomics-based approaches to pancreatic cancer. *TrAC, Trends Anal. Chem.* **2014**, *55*, 94–116.
- (33) (a) Mattar, S. M.; Emwas, A. H.; Calhoun, L. A. Spectroscopic studies of the intermediates in the conversion of 1,4,11,12-tetrahydro-9,10-anthraquinone to 9,10-anthraquinone by reaction with oxygen under basic conditions. *J. Phys. Chem. A* **2004**, *108* (52), 11545–11553. (b) Lam, C.-W.; Law, C.-Y.; Sze, K.-H.; To, K. K.-W. Quantitative metabolomics of urine for rapid etiological diagnosis of urinary tract infection: Evaluation of a microbial-mammalian co-metabolite as a diagnostic biomarker. *Clin. Chim. Acta* **2015**, *438*, 24–28. (c) Simmler, C.; Napolitano, J. G.; McAlpine, J. B.; Chen, S.-N.; Pauli, G. F. Universal quantitative NMR analysis of complex natural samples. *Curr. Opin. Biotechnol.* **2014**, *25*, 51–59.
- (34) Giraudeau, P. Quantitative 2D liquid- state NMR. *Magn. Reson. Chem.* **2014**, *52* (6), 259–272.
- (35) Hyberts, S. G.; Takeuchi, K.; Wagner, G. Poisson-Gap Sampling and Forward Maximum Entropy Reconstruction for Enhancing the Resolution and Sensitivity of Protein NMR Data. *J. Am. Chem. Soc.* **2010**, *132* (7), 2145–2147.
- (36) Rai, R. K.; Sinha, N. Fast and Accurate Quantitative Metabolic Profiling of Body Fluids by Nonlinear Sampling of H-1-C-13 Two-Dimensional Nuclear Magnetic Resonance Spectroscopy. *Anal. Chem.* **2012**, *84* (22), 10005–10011.
- (37) (a) Pathan, M.; Akoka, S.; Tea, I.; Charrier, B.; Giraudeau, P. "Multi-scan single shot" quantitative 2D NMR: a valuable alternative to fast conventional quantitative 2D NMR. *Analyst* **2011**, *136* (15), 3157–3163. (b) Ludwig, C.; Marin-Montesinos, I.; Saunders, M. G.; Emwas, A. H.; Pikramenou, Z.; Hammond, S. P.; Gunther, U. L. Application of ex situ dynamic nuclear polarization in studying small molecules. *Phys. Chem. Chem. Phys.* **2010**, *12* (22), 5868–71.
- (38) Da Silva, L.; Godejohann, M.; Martin, F.-P. J.; Collino, S.; Burkle, A.; Moreno-Villanueva, M.; Bernhardt, J.; Toussaint, O.; Grubeck-Loebenstein, B.; Gonos, E. S.; Sikora, E.; Grune, T.; Breusing, N.; Franceschi, C.; Hervonen, A.; Spraul, M.; Moco, S. High-resolution quantitative metabolome analysis of urine by automated flow injection NMR. *Anal. Chem.* **2013**, *85* (12), 5801–9.
- (39) Sokolenko, S.; McKay, R.; Blondeel, M. J. L.; Lewis, M. J.; Chang, D.; George, B.; Aucoin, M. G. Understanding the variability of compound quantification from targeted profiling metabolomics of 1D-1H-NMR spectra in synthetic mixtures and urine with additional insights on choice of pulse sequences and robotic sampling. *Metabolomics* **2013**, *9*, 887–903.
- (40) Bharti, S. K.; Roy, R. Quantitative H-1 NMR spectroscopy. *TrAC, Trends Anal. Chem.* **2012**, *35*, 5–26.
- (41) (a) Hoffmann, M. M.; Sobstyl, H. S.; Seedhouse, S. J. T-1 relaxation measurement with solvent suppression. *Magn. Reson. Chem.* **2008**, *46* (7), 660–666. (b) Lauridsen, M.; Maher, A. D.; Keun, H.; Lindon, J. C.; Nicholson, J. K.; Nyberg, N. T.; Hansen, S. H.; Cornett, C.; Jaroszewski, J. W. Application of the FLIPSY pulse sequence for increased sensitivity in H-1 NMR-based metabolic profiling studies. *Anal. Chem.* **2008**, *80* (9), 3365–3371.
- (42) McKay, R. T. How the 1D-NOESY Suppresses Solvent Signal in Metabonomics NMR Spectroscopy: An Examination of the Pulse Sequence Components and Evolution. *Concepts Magn. Reson., Part A* **2011**, *38A* (5), 197–220.
- (43) (a) Nguyen, B. D.; Meng, X.; Donovan, K. J.; Shaka, A. J. SOGGY: Solvent-optimized double gradient spectroscopy for water suppression. A comparison with some existing techniques. *J. Magn. Reson.* **2007**, *184* (2), 263–274. (b) Roumestand, C.; Canet, D. Extending the excitation sculpting concept for selective excitation. *J. Magn. Reson.* **2000**, *147* (2), 331–339. (c) Jerschow, A. Unwanted signal leakage in excitation sculpting with single axis gradients. *J. Magn. Reson.* **1999**, *137* (1), 206–214.
- (44) Piotta, M.; Saudek, V.; Sklenar, V. Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. *J. Biomol. NMR* **1992**, *2* (6), 661–665.
- (45) Simpson, A. J.; Brown, S. A. Purge NMR: Effective and easy solvent suppression. *J. Magn. Reson.* **2005**, *175* (2), 340–346.
- (46) Adams, R. W.; Holroyd, C. M.; Aguilar, J. A.; Nilsson, M.; Morris, G. A. "Perfecting" WATERGATE: clean proton NMR spectra from aqueous solution. *Chem. Commun.* **2013**, *49* (4), 358–360.
- (47) Price, W. S. Pulsed-field gradient nuclear magnetic resonance as a tool for studying translational diffusion: Part II. Experimental aspects. *Concepts Magn. Reson.* **1998**, *10* (4), 197–237.
- (48) Mulder, F. A. A.; Spronk, C.; Slijper, M.; Kaptein, R.; Boelens, R. Improved HSQC experiments for the observation of exchange broadened signals. *J. Biomol. NMR* **1996**, *8* (2), 223–228.
- (49) Markley, J. L.; Bax, A.; Arata, Y.; Hilbers, C. W.; Kaptein, R.; Sykes, B. D.; Wright, P. E.; Wuthrich, K. Recommendations for the presentation of NMR structures of proteins and nucleic acids - IUPAC-IUBMB-IUPAB Inter-Union Task Group on the Standardization of Data Bases of Protein and Nucleic Acid Structures Determined by NMR Spectroscopy. *J. Biomol. NMR* **1998**, *12* (1), 1–23.
- (50) Mercier, P.; Lewis, M. J.; Chang, D.; Baker, D.; Wishart, D. S. Towards automatic metabolomic profiling of high-resolution one-dimensional proton NMR spectra. *J. Biomol. NMR* **2011**, *49* (3–4), 307–323.
- (51) Holzgrabe, U.; Deubner, R.; Schollmayer, C.; Waibel, B. Quantitative NMR spectroscopy - Applications in drug analysis. *J. Pharm. Biomed. Anal.* **2005**, *38* (5), 806–812.
- (52) Mo, H.; Raftery, D. Solvent Signal as an NMR Concentration Reference. *Anal. Chem.* **2008**, *80* (24), 9835–9839.
- (53) Bouatra, S.; Aziat, F.; Mandal, R.; Guo, A. C.; Wilson, M. R.; Knox, C.; Bjorn Dahl, T. C.; Krishnamurthy, R.; Saleem, F.; Liu, P.; Dame, Z. T.; Poelzer, J.; Huynh, J.; Yallou, F. S.; Psychogios, N.; Dong, E.; Bogumil, R.; Roehring, C.; Wishart, D. S. *PLoS One* **2013**, *8*, e73076.
- (54) (a) Fonville, J. M.; Maher, A. D.; Coen, M.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. Evaluation of Full-Resolution J-Resolved H-1 NMR Projections of Biofluids for Metabonomics Information Retrieval and Biomarker Identification. *Anal. Chem.* **2010**, *82* (5), 1811–1821. (b) Cloarec, O.; Dumas, M. E.; Craig, A.; Barton, R. H.; Trygg, J.; Hudson, J.; Blancher, C.; Gauguier, D.; Lindon, J. C.; Holmes, E.; Nicholson, J. Statistical total correlation spectroscopy: An exploratory approach for latent biomarker identification from metabolic H-1 NMR data sets. *Anal. Chem.* **2005**, *77* (5), 1282–1289.
- (55) Zheng, C.; Zhang, S.; Ragg, S.; Raftery, D.; Vitek, O. Identification and quantification of metabolites in H-1 NMR spectra by Bayesian model selection. *Bioinformatics* **2011**, *27* (12), 1637–1644.
- (56) (a) Bollard, M. E.; Stanley, E. G.; Lindon, J. C.; Nicholson, J. K.; Holmes, E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. *NMR Biomed.* **2005**,

18 (3), 143–162. (b) Brindle, J. T.; Antti, H.; Holmes, E.; Tranter, G.; Nicholson, J. K.; Bethell, H. W. L.; Clarke, S.; Schofield, P. M.; McKilligin, E.; Mosedale, D. E.; Grainger, D. J. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1 H-NMR-based metabolomics. *Nat. Med.* **2002**, *8* (12), 1439–1445. (c) Waters, N. J.; Waterfield, C. J.; Farrant, R. D.; Holmes, E.; Nicholson, J. K. Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity. *Chem. Res. Toxicol.* **2005**, *18* (4), 639–654. (d) Ringeissen, S.; Connor, S. C.; Brown, H. R.; Sweatman, B. C.; Hodson, M. P.; Kenny, S. P.; Haworth, R. I.; McGill, P.; Price, M. A.; Aylott, M. C.; et al. Potential urinary and plasma biomarkers of peroxisome proliferation in the rat: identification of N-methylnicotinamide and N-methyl-4-pyridone-3-carboxamide by 1H nuclear magnetic resonance and high performance liquid chromatography. *Biomarkers* **2003**, *8* (3–4), 240–271.

(57) Dieterle, F.; Ross, A.; Schlotterbeck, G.; Senn, H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabolomics. *Anal. Chem.* **2006**, *78* (13), 4281–4290.

(58) Torgrip, R. J. O.; Åberg, K.; Alm, E.; Schuppe-Koistinen, I.; Lindberg, J. A note on normalization of biofluid 1D 1 H-NMR data. *Metabolomics* **2008**, *4* (2), 114–121.

(59) Dunn, W. B.; Broadhurst, D. I.; Atherton, H. J.; Goodacre, R.; Griffin, J. L. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. *Chem. Soc. Rev.* **2011**, *40* (1), 387–426.

(60) (a) Kamal, M. A.; Priyamvada, S.; Anbazhagan, A. N.; Jabir, N. R.; Tabrez, S.; Greig, N. H. Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation. *CNS Neurol. Disord.: Drug Targets* **2014**, *13* (2), 338–46. (b) Dawiskiba, T.; Deja, S.; Mulak, A.; Zabeł, A.; Jawien, E.; Pawelka, D.; Banasik, M.; Mastalerz-Migas, A.; Balcerzak, W.; Kaliszewski, K.; Skora, J.; Barc, P.; Korta, K.; Pormanczuk, K.; Szyber, P.; Litarski, A.; Mlynarz, P. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases. *World Journal of Gastroenterology* **2014**, *20* (1), 163–174. (c) Deja, S.; Barg, E.; Mlynarz, P.; Basiak, A.; Willak-Janc, E. H-1 NMR-based metabolomics studies of urine reveal differences between type 1 diabetic patients with high and low HbA1c values. *J. Pharm. Biomed. Anal.* **2013**, *83*, 43–48. (d) Vazquez-Fresno, R.; Llorach, R.; Marinic, J.; Tulipani, S.; Garcia-Aloy, M.; Espinosa-Martos, I.; Jimenez, E.; Rodriguez, J. M.; Andres-Lacueva, C. Urinary metabolomic fingerprinting after consumption of a probiotic strain in women with mastitis. *Pharmacol. Res.* **2014**, *87*, 160–165. (e) Nagrath, D.; Caneba, C.; Karedath, T.; Bellance, N. Metabolomics for mitochondrial and cancer studies. *Biochim. Biophys. Acta, Bioenerg.* **2011**, *1807* (6), 650–663. (f) Wang, X.; Zhang, A.; Han, Y.; Wang, P.; Sun, H.; Song, G.; Dong, T.; Yuan, Y.; Yuan, X.; Zhang, M.; Xie, N.; Zhang, H.; Dong, H.; Dong, W. Urine Metabolomics Analysis for Biomarker Discovery and Detection of Jaundice Syndrome in Patients With Liver Disease. *Mol. Cell. Proteomics* **2012**, *11* (8), 370–380.

(61) Luszczyk, E. R.; Paulo, J. A.; Saltzman, J. R.; Kadiyala, V.; Banks, P. A.; Beilman, G.; Conwell, D. L. Urinary 1H-NMR metabolomics can distinguish pancreatitis patients from healthy controls. *Pancreatol.* **2013**, *14* (2), 161–70.

(62) Srivastava, S.; Roy, R.; Singh, S.; Kumar, P.; Dalela, D.; Sankhwar, S. N.; Goel, A.; Sonkar, A. A. Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy. *Cancer biomarkers: section A of Disease markers* **2010**, *6* (1), 11–20.

(63) Ladep, N. G.; Dona, A. C.; Lewis, M. R.; Crossey, M. M.; Lemoine, M.; Okeke, E.; Shimakawa, Y.; Duguru, M.; Njai, H. F.; Fye, H. K.; Taal, M.; Chetwood, J.; Kasstan, B.; Khan, S. A.; Garside, D. A.; Wijeyesekera, A.; Thillainayagam, A. V.; Banwat, E.; Thursz, M. R.; Nicholson, J. K.; Njie, R.; Holmes, E.; Taylor-Robinson, S. D. Discovery and validation of urinary metabolotypes for the diagnosis of hepatocellular carcinoma (HCC) in West Africans. *Hepatology* **2014**, *60*, 1291.

(64) Dessi, A.; Atzori, L.; Noto, A.; Visser, G. H.; Gazzolo, D.; Zanardo, V.; Barberini, L.; Puddu, M.; Ottonello, G.; Atzei, A.; De Magistris, A.; Lussu, M.; Murgia, F.; Fanos, V. Metabolomics in newborns with

intrauterine growth retardation (IUGR): urine reveals markers of metabolic syndrome. *J. Matern.-Fetal Neonat. Med.* **2011**, *24* (Suppl 2), 35–9.

(65) Moltu, S. J.; Sachse, D.; Blakstad, E. W.; Strommen, K.; Nakstad, B.; Almaas, A. N.; Westerberg, A. C.; Ronnestad, A.; Braekke, K.; Veierod, M. B.; Iversen, P. O.; Rise, F.; Berg, J. P.; Drevon, C. A. Urinary metabolite profiles in premature infants show early postnatal metabolic adaptation and maturation. *Nutrients* **2014**, *6* (5), 1913–30.

(66) (a) Saude, E. J.; Slupsky, C. M.; Sykes, B. D. Optimization of NMR analysis of biological fluids for quantitative accuracy. *Metabolomics* **2006**, *2* (3), 113–123. (b) Rasmussen, L. G.; Savorani, F.; Larsen, T. M.; Dragsted, L. O.; Astrup, A.; Engelsen, S. B. Standardization of factors that influence human urine metabolomics. *Metabolomics* **2011**, *7* (1), 71–83. (c) Pelantova, H.; Buganova, M.; Anyz, J.; Zelezna, B.; Maletinska, L.; Novak, D.; Haluzik, M.; Kuzma, M. Strategy for NMR metabolomic analysis of urine in mouse models of obesity- from sample collection to interpretation of acquired data. *J. Pharm. Biomed. Anal.* **2015**, *115*, 225–235.

(67) Walsh, M. C.; Brennan, L.; Malthouse, J. P. G.; Roche, H. M.; Gibney, M. J. Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. *Am. J. Clin. Nutr.* **2006**, *84* (3), 531–539.

(68) Lombardini, J.; Schaffer, S.; Azuma, J.; Odle, J.; Glass, E.; Czarnecki-Maulden, G.; Baker, D., Urinary Excretion of Taurine as a Function of Taurine Intake: Potential for Estimating Taurine Bioavailability in the Adult Cat. In *Taurine*; Springer: 1992; Vol. 315, pp 55–62.

(69) Beckonert, O.; Keun, H. C.; Ebbels, T. M. D.; Bundy, J.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. Metabolic profiling, metabolomic and metabolomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. *Nat. Protoc.* **2007**, *2* (11), 2692–2703.

(70) (a) Yao, S.; Keizer, D. W. Nutation frequency modulation on NMR signal of nuclear spins in chemical exchange with solvent water under the BEST conditions. *Magn. Reson. Chem.* **2014**, *52* (4), 190–194. (b) Wu, P. S. C.; Otting, G. Rapid pulse length determination in high-resolution NMR. *J. Magn. Reson.* **2005**, *176* (1), 115–119.

(71) Grzesiek, S.; Bax, A. The importance of not saturating water in protein NMR. Application to sensitivity enhancement and NOE measurements. *J. Am. Chem. Soc.* **1993**, *115* (26), 12593–12594.

(72) Prost, E.; Sizun, P.; Piotto, M.; Nuzillard, J. M. A simple scheme for the design of solvent-suppression pulses. *J. Magn. Reson.* **2002**, *159* (1), 76–81.

(73) (a) Rist, M.; Muhle-Goll, C.; Görling, B.; Bub, A.; Heissler, S.; Watzl, B.; Luy, B. Influence of Freezing and Storage Procedure on Human Urine Samples in NMR-Based Metabolomics. *Metabolites* **2013**, *3* (2), 243–258. (b) Beckonert, O.; Keun, H. C.; Ebbels, T. M. D.; Bundy, J.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. Metabolic profiling, metabolomic and metabolomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. *Nat. Protoc.* **2007**, *2* (11), 2692–2703.

(74) Bharti, S.; Sinha, N.; Joshi, B.; Mandal, S.; Roy, R.; Khetrapal, C. Improved quantification from 1H-NMR spectra using reduced repetition times. *Metabolomics* **2008**, *4* (4), 367–376.

(75) Wishart, D. S. Quantitative metabolomics using NMR. *TrAC, Trends Anal. Chem.* **2008**, *27* (3), 228–237.

(76) Davis, V. W.; Schiller, D. E.; Eurich, D.; Bathe, O. F.; Sawyer, M. B. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. *Ann. Surg. Oncol.* **2013**, *20* (Suppl 3), S415–23.

(77) Davis, V. W.; Schiller, D. E.; Eurich, D.; Sawyer, M. B. Urinary metabolomic signature of esophageal cancer and Barrett's esophagus. *World journal of surgical oncology* **2012**, *10*, 271.

(78) Diaz, S. O.; Pinto, J.; Graca, G.; Duarte, I. F.; Barros, A. S.; Galhano, E.; Pita, C.; Almeida, M. d. C.; Goodfellow, B. J.; Carreira, I. M.; Gil, A. M. Metabolic biomarkers of prenatal disorders: an exploratory NMR metabolomics study of second trimester maternal urine and blood plasma. *J. Proteome Res.* **2011**, *10* (8), 3732–42.